Bioventus Inc. (NASDAQ:BVS) Stock Has Average Target Price of $16.80

Shares of Bioventus Inc. (NASDAQ:BVS) have been given an average rating of “Buy” by the six ratings firms that are currently covering the stock, MarketBeat reports. Six research analysts have rated the stock with a buy recommendation. The average 1 year price target among brokers that have covered the stock in the last year is $16.80.

A number of equities research analysts have recently weighed in on the stock. Weiss Ratings upgraded shares of Bioventus from a “hold (c+)” rating to a “buy (b-)” rating in a report on Thursday, October 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $15.00 price objective on shares of Bioventus in a research report on Monday, August 17th. Craig Hallum reiterated a “buy” rating and set a $18.00 target price on shares of Bioventus in a research note on Thursday, August 6th. Canaccord Genuity Group increased their target price on Bioventus from $15.00 to $19.00 and gave the company a “buy” rating in a report on Monday, August 17th. Finally, Barrington Research set a $18.00 price target on Bioventus in a report on Thursday, August 6th.

Bioventus Stock Up 5.6%

BVS stock opened at $15.04 on Friday. The company’s 50 day moving average price is $13.68 and its 200 day moving average price is $11.66. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.17 and a current ratio of 1.69. Bioventus has a fifty-two week low of $6.47 and a fifty-two week high of $15.89. The firm has a market capitalization of $1.26 billion, a price-to-earnings ratio of 19.53, a PEG ratio of 1.81 and a beta of 0.64.

Bioventus (NASDAQ:BVS) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $0.22 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.22. Bioventus had a net margin of 9.36% and a return on equity of 28.08%. The company had revenue of $153.21 million during the quarter. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. On average, equities research analysts anticipate that Bioventus will post 0.79 EPS for the current fiscal year.

Institutional Trading of Bioventus

Institutional investors have recently modified their holdings of the stock. Hillsdale Investment Management Inc. boosted its holdings in shares of Bioventus by 148.7% in the 1st quarter. Hillsdale Investment Management Inc. now owns 671,139 shares of the company’s stock valued at $6,128,000 after buying an additional 401,230 shares in the last quarter. Engine Capital Management LP acquired a new stake in Bioventus during the 1st quarter worth $2,876,000. Inspire Investing LLC acquired a new stake in Bioventus during the 1st quarter worth $1,670,000. Sei Investments Co. raised its stake in Bioventus by 160.7% during the 1st quarter. Sei Investments Co. now owns 289,648 shares of the company’s stock worth $2,644,000 after acquiring an additional 178,539 shares in the last quarter. Finally, Globeflex Capital L P purchased a new stake in Bioventus in the second quarter valued at $1,566,000. Hedge funds and other institutional investors own 62.94% of the company’s stock.

Bioventus Company Profile

Bioventus Inc is a medical device and biologics company focused on developing and commercializing products that support bone healing, joint health and surgical recovery. Its portfolio is designed to help healthcare professionals treat musculoskeletal conditions and improve patient outcomes through noninvasive therapies, injectable products and biologic solutions.

The company’s offerings include bone stimulation systems such as EXOGEN, which is used to support fracture healing, as well as injectable osteoarthritis treatments including DUROLANE and GELSYN-3.